DN-108
DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes[1].
Product Specifications
CAS Number
195604-21-8
UNSPSC
12352100
Target
PPAR
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Field of Research
Metabolic Disease
Smiles
O=C1SC(CC2=CC=C(NC(C3(CC3)C4=CC=CC=C4)=O)C=C2)C(N1)=O
Molecular Formula
C20H18N2O3S
Molecular Weight
366.43
References & Citations
[1]Ueda N, et al. Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5- (4- (1-phenyl-1-cyclopropanecarbonylamino) benzyl) -thiazolidine-2 ,4-dio ne. Arzneimittelforschung. 1998 Jun;48 (6) :651-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARγ
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
